Aehr Test Systems is engaged in test systems for burning-in and testing logic, optical, and memory integrated circuits... Show more
Aehr Test Systems, headquartered in Fremont, California, designs and manufactures test and burn-in equipment used to stress-test semiconductor devices before they ship. The company's products include the FOX-P family of wafer-level test and burn-in systems, FOX WaferPak contactors, FOX DiePak carriers, and the high-power Sonoma family of package-level test and burn-in solutions for AI accelerators, GPUs, and high-performance computing processors.
Aehr operates in a specialized segment of the semiconductor capital equipment market, serving applications in artificial intelligence, silicon photonics, data centers, automotive and electric vehicles, and industrial power semiconductors. Investors follow the stock closely because the company has positioned its burn-in technology around the growing reliability requirements of AI processors, where a single defective device can be costly at data-center scale. Its competitive set includes established test and burn-in equipment providers such as Teradyne (TER), which has also signaled entry into AI-focused burn-in markets.
Over the last 30 days, AEHR declined from $99.62 at the close on September 30 to $54.89 at the close on October 30, a drop of approximately 44.9%. The move was not a single-day event but a steady grind lower punctuated by sharp sessions, including an 11.7% single-day decline on October 6.
The last quarter tells a broader, more volatile story. The stock closed near $76.87 on July 30, surged to a closing high of $145.61 on August 17 after strong earnings and guidance, and then gave back those gains through September and October. Measured from the end of July, the stock is down roughly 28.6% over the quarter, even as it remains well above its 52-week low of $18.70. The overall trend has been characterized by rapid appreciation followed by a pronounced correction toward the end of the period.
The 30-day decline followed a period of exceptional momentum. After rallying sharply on fiscal fourth-quarter results and an aggressive fiscal 2027 outlook, the stock entered October near $107 before a decisive reversal. Market commentary during the period pointed to several contributing factors rather than a single catalyst.
Valuation emerged as a recurring theme. Aehr's price-to-sales ratio of roughly 34 was substantially above its historical median near 4.8, and some independent valuation models placed the stock's estimated intrinsic value well below its traded price. Reports also highlighted sustained insider selling of approximately $62.5 million over the trailing 12 months with no insider purchases, which weighed on sentiment.
Company-specific news remained broadly positive. On October 7, Aehr announced approximately $6 million in follow-on Sonoma production orders from its lead hyperscale customer for a next-generation AI processor, and on October 29 it appointed former Meta infrastructure executive Vijay Rao to its board. Positioning ahead of the November 2 earnings report, however, appears to have kept sellers in control as investors reduced risk into the print.
The quarter's defining event was Aehr's fiscal 2026 fourth-quarter report on July 14. The company posted revenue of $18.8 million, up 34% year over year, and non-GAAP earnings of $0.11 per share versus expectations for a loss. Record quarterly bookings of $60.7 million lifted backlog to $80.6 million, with an effective backlog of roughly $100 million including post-quarter orders.
Management guided fiscal 2027 revenue to between $130 million and $150 million, representing 160% to 200% year-over-year growth. Analysts responded favorably, with Lake Street raising its price target to $110 from $56 while reiterating a Buy rating. The stock's mid-August peak reflected enthusiasm around AI-driven burn-in demand and a record backlog, before elevated valuations and profit-taking triggered a multi-week correction that extended into late October.
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies from a platform offering hundreds of AI-driven bots that trade thousands of tickers. Only top-performing and most relevant bots appear in this section, making it a useful starting point for traders evaluating algorithmic approaches. The bots vary by strategy, timeframe, and performance metrics, so the page offers a snapshot of what is currently working across the market rather than a single recommendation. Traders interested in systematic, data-driven trading can review the featured robots to see which strategies align with their own objectives.
Aehr's first-quarter fiscal 2027 report on November 2 is the near-term focal point, with consensus estimates near $27.5 million in revenue and a projected year-over-year surge in earnings per share. Investors will watch whether the company's record backlog converts into shipped revenue on schedule and whether guidance for fiscal 2027 is reaffirmed or adjusted.
Beyond earnings, key factors include demand trends for AI accelerators and silicon photonics, execution on large hyperscale orders, competitive pressure from larger test-equipment vendors, and the pace of any new customer wins. Macroeconomic conditions affecting semiconductor capital spending and data-center investment will also influence sentiment, as will valuation multiples that remain elevated relative to historical norms. These factors do not constitute investment advice but frame the variables most likely to shape the stock's trajectory in the months ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Oscillator for AEHR moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 29 of the 31 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on AEHR as a result. In 71 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for AEHR just turned positive on November 03, 2026. Looking at past instances where AEHR's MACD turned positive, the stock continued to rise in 35 of 38 cases over the following month. The odds of a continued upward trend are 90%.
Following a +21.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEHR advanced for three days, in 243 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
AEHR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 63 cases where AEHR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The 10-day moving average for AEHR crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for AEHR entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.970) is normal, around the industry mean (5.670). AEHR has a moderately low P/E Ratio (-232.913) as compared to the industry average of (68.795). Projected Growth (PEG Ratio) (0.927) is also within normal values, averaging (0.801). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (51.813) is also within normal values, averaging (27.897).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. AEHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock better than average.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of burn-in and test equipment for semiconductor manufacturing
Industry ElectronicProductionEquipment